20-F: Inventiva S.A. Reports Financial Results for Fiscal Year 2024

Inventiva S.A.'s 20-F filing summarizes the company's financial performance for the year ended December 31, 2024, highlighting its focus on lanifibranor development and financial strategies.

Summary

• Inventiva S.A., a clinical-stage biopharmaceutical company, has released its financial results for the fiscal year ending December 31, 2024.
• The company's primary focus remains on the development of lanifibranor for MASH treatment.
• As of December 31, 2024, Inventiva had 96.6 million in cash and cash equivalents.
• The company incurred a net loss of 184.2 million for the year ended December 31, 2024.
• Revenue for the year was 9.2 million, primarily from a milestone payment related to the CTTQ License Agreement.
• Research and development expenses totaled 90.9 million for the year.
• The company is pursuing additional funding through potential securities offerings and strategic transactions.
• A 2025 Pipeline Prioritization Plan is under negotiation with the Workers Council, involving a workforce reduction of approximately 50%.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive aspects such as ongoing clinical trials and partnerships, the significant net loss and need for additional funding raise concerns. The sentiment is cautiously negative.

Positives

• The company is actively pursuing additional funding to support its operations.
• The company has a strategic focus on lanifibranor, its lead product candidate.
• The company has partnerships with CTTQ and Hepalys to support the development and commercialization of lanifibranor.

Negatives

• The company incurred a significant net loss of 184.2 million for the fiscal year 2024.
• The company's current cash and cash equivalents are not sufficient to cover its operating needs for the next 12 months.
• The company is considering a workforce reduction of approximately 50%.

Risks

• The company requires substantial additional funding, which may not be available on acceptable terms.
• The company is heavily dependent on the success of its product candidate lanifibranor.
• The regulatory approval processes are lengthy, time-consuming, and inherently unpredictable.
• Clinical development is a lengthy and expensive process with an uncertain outcome.
• The company may not realize the benefits expected through partnerships with CTTQ and Hepalys.
• The company currently has no marketing and sales organization.
• The company faces significant competition for its drug discovery and development efforts.
• The company may encounter substantial delays in its clinical trials or fail to demonstrate safety and efficacy.
• The company relies completely on third parties to manufacture its drug supplies.
• Voting control is concentrated in the hands of key individuals and significant shareholders.
• The rights of shareholders in companies subject to French corporate law differ in material respects from the rights of shareholders of corporations incorporated in the United States.

Future Outlook

The company expects to continue to incur significant expenses and increasing operating losses for the foreseeable future as it advances clinical development and prepares for potential commercialization of lanifibranor. The company estimates that its existing cash and cash equivalents and expected potential additional sources of funding would enable it to finance its activities until the end of the third quarter of 2026, as currently planned.

Industry Context

The document mentions that other MASH therapies in development may become commercially available during the conduct of Inventiva's ongoing NATiV3 trial and its planned Phase 3 trial in patients with MASH and compensated cirrhosis. For example, in March 2024, Madrigal announced that it had received FDA approval of Rezdiffra for the treatment of patients with MASH with moderate to advanced liver fibrosis.

Comparison to Industry Standards

• The document mentions Madrigal Pharmaceuticals' Rezdiffra as a commercially available MASH therapy, setting a benchmark for regulatory approval and market competition.
• Novo Nordisk's semaglutide is also mentioned as a potential competitor, with Phase 3 clinical trial results expected to support a marketing authorization application in 2025.
• Boehringer Ingelheim, Akero Therapeutics, and 89Bio are identified as competitors with ongoing Phase 3 clinical trials for MASH treatments.

Related Party Transactions

• The document mentions agreements with Pierre Broqua, BVF Partners, New Enterprise Associates, Sofinnova, and Yiheng.

Stakeholder Impact

• Shareholders may experience dilution due to potential capital increases.
• Employees may be affected by the proposed workforce reduction.
• Patients may benefit from the potential development and commercialization of lanifibranor.

Next Steps

• Continue the ongoing and future development of lanifibranor.
• Develop, maintain, expand and protect the intellectual property portfolio.
• Manufacture, or have manufactured, clinical and commercial supplies of product candidates.
• Seek marketing approvals for current and future product candidates that successfully complete clinical trials.
• Establish a sales, marketing and distribution infrastructure to commercialize any product candidate for which marketing approval is obtained.
• Hire additional clinical, quality control and scientific personnel.
• Continue to incur costs associated with operating as a public company in the United States.

Key Dates

Keywords

lanifibranor, MASH, clinical trials, financial results, Inventiva, CTTQ, Hepalys, funding, biopharmaceutical, research and development